Fort Worth-Based Barricade Therapeutics Secures $14 Million CPRIT Grant to Advance Colorectal Cancer Treatment

Barricade Therapeutics, Corp. has received a $14,005,035 grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support the Phase I clinical development of Barricade’s innovative therapeutic candidate BT-1501 for APC mut advanced colorectal cancer patients.